Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Oct;10(19):1048.
doi: 10.21037/atm-22-4343.

Future directions in asthma pharmacogenomics

Scott T Weiss  1
Affiliations
Editorial

Future directions in asthma pharmacogenomics

Scott T Weiss. Ann Transl Med. 2022 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-4343/coif). STW reports that he has received grants from the NIH; receives payment from UpToDate for articles he has written; and he is on the Board of Histolix, a digital pathology company. The author has no other conflicts of interest to declare.

Comment on

References

    1. Li J, Qiu C. Recent advances in pharmacogenomics research of anti-asthmatic drugs: a narrative review. Ann Transl Med 2022;10:369. 10.21037/atm-22-291 - DOI - PMC - PubMed
    1. Baek SH, Foer D, Cahill KN, et al. Systems Approaches to Treatment Response to Imatinib in Severe Asthma: A Pilot Study. J Pers Med 2021;11:240. 10.3390/jpm11040240 - DOI - PMC - PubMed
    1. Jackson DJ, Bacharier LB, Gergen PJ, et al. Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet 2022;400:502-11. 10.1016/S0140-6736(22)01198-9 - DOI - PMC - PubMed